Comment: Neuroleptic Malignant Syndrome Versus Serotonin Syndrome: The Search for a Diagnostic Tool

Abstract

View all access options for this article.

Sokoro

AAH

, Zivot

, Ariano

. Neuroleptic malignant syndrome versus serotonin syndrome: the search for a diagnostic tool. Ann Pharmacother 2011; 45:e50. DOI 10.1345/aph.1P787

Dunkley

, Isbister

, Sibbritt

, Dawson

, Whyte

. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003; 96:635–42.

Steenbach

. The serotonin syndrome. Am J Psychiatry 1991; 148:705–13.

Gillman

. The serotonin syndrome and its treatment. J Psychopharmacol 1999; 13:100–9.

Mason

, Morris

, Balcezak

. Serotonin syndrome: presentation of 2 cases and review of the literature. Medicine (Baltimore) 2000; 79:201–9.

Boyer

, Shannon

. The serotonin syndrome. N Engl J Med 2005; 352:1112–120.

Neary

, King

, Pacek

. Drugs and pheochromocytoma–don't be fooled by every elevated metanephrine. N Engl J Med 2011; 364:2268–70.

Davis

, Caroff

, Mann

. Treatment of neuroleptic malignant syndrome. Psychiat Ann 2000; 30:325–31.

Gertz

, Schmidt

. Low melanin content of substantia nigra in a case of neuroleptic malignant syndrome. Pharmacopsychiatry 1991; 24:93–5.

10.

Reulbach

, Dutsch

, Biermann

. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care 2007; 11:R4. DOI 10.1186/cc5148